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BAFF, APRIL and BAFF‑R are key proteins involved in the development of B‑lymphocytes and 
autoimmunity. Additionally, BAFF, APRIL and BAFFR polymorphisms were associated with immune‑
mediated conditions, being BAFF GCTGT>A a shared insertion‑deletion genetic variant for several 
autoimmune diseases. Accordingly, we assessed whether BAFF, APRIL and BAFFR represent 
novel genetic risk factors for Immunoglobulin‑A vasculitis (IgAV), a predominantly B‑lymphocyte 
inflammatory condition. BAFF rs374039502, which colocalizes with BAFF GCTGT>A, and two 
tag variants within APRIL (rs11552708 and rs6608) and BAFFR (rs7290134 and rs77874543) were 
genotyped in 386 Caucasian IgAV patients and 806 matched healthy controls. No genotypes or alleles 
differences were observed between IgAV patients and controls when BAFF, APRIL and BAFFR variants 
were analysed independently. Likewise, no statistically significant differences were found in the 
genotype and allele frequencies of BAFF, APRIL or BAFFR when IgAV patients were stratified according 
to the age at disease onset or to the presence/absence of gastrointestinal (GI) or renal manifestations. 
Similar results were disclosed when APRIL and BAFFR haplotypes were compared between IgAV 
patients and controls and between IgAV patients stratified according to the clinical characteristics 
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mentioned above. Our results suggest that BAFF, APRIL and BAFFR do not contribute to the genetic 
network underlying IgAV.
B cell-activating factor (BAFF, also known as B-lymphocyte stimulator or BlyS) and a proliferation-inducing 
ligand (APRIL) are cytokines expressed by antigen-presenting cells that play a crucial role in the development of 
B-lymphocytes1–4. BAFF receptor (BAFF-R) is the major mediator of BAFF-dependent costimulatory responses 
in circulating peripheral B-lymphocytes5, essential for its survival and maturation. Several pieces of evidence 
revealed that BAFF, APRIL and BAFF-R are molecules also involved in  autoimmunity6–8. In this regard, an influ-
ence of BAFF, APRIL and BAFFR polymorphisms was observed on several immune-mediated  conditions9–11, 
being BAFF GCTGT>A a shared insertion-deletion variant for multiple sclerosis, systemic lupus erythematosus 
(SLE), and rheumatoid  arthritis9,12.
Immunoglobulin-A vasculitis (IgAV), formerly called Henoch-Schönlein purpura (HSP), is an inflammatory 
small-sized blood vessel disease, more common in children and rarer but more serious in  adults13–15. The classic 
clinical triad of IgAV consists of palpable purpura, arthralgias/arthritis and gastrointestinal (GI) tract involve-
ment. Renal manifestations are also common in affected patients and constitutes the most serious complication of 
the  disease16–18. IgA1-predominant immune deposits in the vessel walls are the defining pathophysiologic feature 
of  IgAV13, supporting the hypothesis that this vasculitis is predominantly a B-lymphocyte mediated disease. 
Furthermore, IgAV has a multifactorial aetiology in which genes play a relevant role in both the predisposition 
and severity of the  disease19–21.
Taken all these considerations into account, this study aimed to determine, for the first time, whether BAFF, 
APRIL and BAFFR represents novel genetic risk factors for the pathogenesis of IgAV. For this purpose, BAFF 
rs374039502 polymorphism, which colocalizes with the BAFF GCTGT>A insertion-deletion variant men-
tioned above, and two tag polymorphisms within APRIL (rs11552708 and rs6608) and BAFFR (rs7290134 and 
rs77874543), which cover most of the variability of both genes, were genotyped in the largest series of Caucasian 
patients diagnosed with IgAV ever assessed for genetic studies.
Patients and methods
Study population. A series of 386 unrelated Spanish patients of European ancestry who fulfilled both 
Michel et al.22 and the American College of  Rheumatology23 classification criteria for IgAV-HSP were included 
in the present study. Centres involved in the recruitment of these patients included Hospital Universitario Mar-
qués de Valdecilla (Santander), Hospital Universitario San Cecilio (Granada), Hospital Universitario de Bellvitge 
(Barcelona), Hospital Universitario Lucus Augusti (Lugo), Hospital Universitario Central de Asturias (Oviedo), 
Hospital Universitario Severo Ochoa and Hospital Universitario de La Princesa (Madrid), Hospital Universitario 
Virgen del Rocío (Sevilla) and Hospital Universitario de Basurto (Bilbao). Information on the main clinical 
features of these patients is shown in Table 1. For GI manifestations, bowel angina was considered present if 
there was diffuse abdominal pain that worsened after meals, or bowel ischemia usually with bloody diarrhoea. 
GI bleeding was defined as the presence of melena, haematochezia, or a positive test for occult blood in the 
stool. Renal manifestations were defined to be present if at least one of the following findings was observed: 
haematuria, proteinuria, or nephrotic syndrome at any time over the clinical course of the disease and/or renal 
sequelae (persistent renal involvement) at last follow-up. With regard to treatment, glucocorticoids were used 
in patients with severe GI and/or renal manifestations. Mycophenolate or azathioprine were added to gluco-
corticoids in refractory patients. Cyclophosphamide and plasma exchange were required in two patients due to 
life-threatening manifestations.
In addition, a set of 806 sex and ethnically matched healthy controls without history of cutaneous vasculitis or 
any other autoimmune disease, constituted by blood donors from Hospital Universitario Marqués de Valdecilla 
(Santander) and National DNA Bank Repository (Salamanca), was also included in this study.
For experiments involving humans and the use of human blood samples, all the methods were carried out in 
accordance with the approved guidelines and regulations, according to the Declaration of Helsinki. All experi-
mental protocols were approved by the Ethics Committees of Cantabria (for Hospital Universitario Marqués de 
Valdecilla, Santander), Ethics Committee of clinical research of Granada (for Hospital Universitario San Cecilio, 
Granada), Ethics Committee of clinical research of Barcelona (for Hospital Universitario de Bellvitge, Barcelona), 
Ethics Committee of clinical research of Galicia (for Hospital Universitario Lucus Augusti, Lugo), Ethics Commit-
tee of clinical research of Asturias (for Hospital Universitario Central de Asturias, Oviedo), Ethics Committee of 
clinical research of Madrid (for Hospital Universitario Severo Ochoa and Hospital Universitario de la Princesa, 
Madrid), Ethics Committee of clinical research of Sevilla (for Hospital Universitario Virgen del Rocío, Sevilla) 
and Ethics Committee of clinical research of Euskadi (for Hospital Universitario de Basurto, Bilbao). Informed 
written consent was obtained from all subjects.
Single nucleotide polymorphisms selection and genotyping methods. Genomic deoxyribonu-
cleic acid (DNA) from all the individuals was extracted from peripheral blood using REALPURE `SSS´ kit 
(RBME04, REAL, Durviz S.L., Spain).
Patients with IgAV and healthy controls were genotyped for the BAFF rs374039502 single nucleotide poly-
morphism using a custom TaqMan assay (ID: AH0JGPG) with the following primers: forward 5′-GAC AGC 
ATC CCG GTT TTC ATT TTA T-3′ and reverse 5′-TGT AAA CTG TTA AAT GAA GTA AAC AGT TAA AAC TGA -3′. 
In addition, all individuals recruited in this study were genotyped for two tag genetic variants within APRIL 
(rs11552708 and rs6608) and two tag polymorphisms within BAFFR (rs7290134 and rs77874543), using prede-
signed TaqMan assays (C_25630192_20 for rs11552708, C_247220_20 for rs6608, C_2189968_1_ for rs7290134 
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and C_102764384_20 for rs77874543). Tagging of APRIL and BAFFR was performed using data from the 1000 
Genomes Project (http:// www. inter natio nalge nome. org/) and the Haploview v4.2 software (http:// broad. mit. 
edu/ mpg/ haplo view), and considering the  r2 threshold set at 0.8 and minimum minor allele frequency at 0.05. 
The linkage disequilibrium pattern of the APRIL and BAFFR polymorphisms analysed in this study is shown as 
Supplementary Figure 1 and Supplementary Figure 2 online, respectively.
Genotyping was performed in a QuantStudio™ 7 Flex Real-Time polymerase chain reaction system, according 
to the conditions recommended by the manufacturer (Applied Biosystems, Foster City, CA, USA).
Negative controls and duplicate samples were included to check the accuracy of the genotyping.
Statistical analyses. All genotype data were checked for deviation from Hardy–Weinberg equilibrium 
(HWE).
Differences in genotype and allele frequencies of BAFF, APRIL and BAFFR as well as differences in haplotype 
frequencies of APRIL and BAFFR were evaluated between patients with IgAV and healthy controls and between 
patients with IgAV stratified according to specific clinical characteristics of the disease (age at disease onset or 
presence/absence of GI or renal manifestations).
First, comparisons were performed considering each BAFF, APRIL and BAFFR polymorphism independently. 
Both genotype and allele frequencies were calculated and compared between the groups mentioned above by 
chi-square or Fisher tests when necessary (expected values below 5). Strength of association was estimated using 
odds ratios (OR) and 95% confidence intervals (CI).
Subsequently, allelic combinations (haplotypes) of both APRIL and BAFFR polymorphisms were carried out. 
Haplotype frequencies were calculated by the Haploview v4.2 software (http:// broad. mit. edu/ mpg/ haplo view) 
and then compared between the groups mentioned above by chi-square or Fisher tests. Strength of association 
was estimated by OR and 95% CI.
P-values lower than 0.05 were considered as statistically significant.
All analyses were performed with the STATA statistical software 12/SE (Stata Corp., College Station, TX, 
USA).
Results
The genotyping success rate for each polymorphism evaluated in this study was 99.4% for BAFF rs374039502 
and APRIL rs11552708, 99.6% for APRIL rs6608, 99.7% for BAFFR rs7290134 and 99.3% for BAFFR rs77874543.
No evidence of departure from HWE was observed at the 5% significance level.
Genotype and allele frequencies of BAFF, APRIL and BAFFR variants were similar to those reported for 
populations of European origin in the 1000 Genomes Project (http:// www. inter natio nalge nome. org/).
Differences in genotype and allele frequencies of BAFF, APRIL and BAFFR between patients 
with IgAV and healthy controls. Firstly, we compared genotype and allele frequencies of each BAFF, 
APRIL and BAFFR variant assessed independently between patients with IgAV and healthy controls.
As shown in Table 2, no statistically significant differences in BAFF, APRIL and BAFFR frequencies were 
disclosed when patients with IgAV were compared to healthy controls.
Differences in genotype and allele frequencies of BAFF, APRIL and BAFFR between patients 
with IgAV stratified according to specific clinical characteristics of the disease. Subsequently, 
we compared genotype and allele frequencies of each BAFF, APRIL and BAFFR variant assessed independently 
between patients with IgAV stratified according to specific clinical characteristics of the disease.
Table 1.  Main clinical features of the 386 patients with IgAV included in the study. IgAV: IgA vasculitis; IQR: 
interquartile range; GI: gastrointestinal. a At any time over the clinical course of the disease. b At last follow-up.
% (n)
Children (age ≤ 20 years)/adults (age > 20 years) (n) 309/77
Percentage of females 47.9
Age at disease onset (years, median [IQR]) 7 [5–19]
Duration of follow-up (years, median [IQR]) 1 [1–3]
Palpable purpura and/or maculopapular rash 100 (386)
Arthralgia and/or arthritis 54.9 (212)
GI manifestations (if “a” and/or “b”) 53.6 (207)
a) Bowel angina 50.8 (196)
b) GI bleeding 17.1 (66)
Renal manifestations (if any of the following characteristics) 37.0 (143)
a)  Haematuriaa 35.5 (137)
b)  Proteinuriaa 33.7 (130)
c) Nephrotic  syndromea 5.7 (22)
d) Renal sequelae (persistent renal involvement)b 6.7 (26)
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Since IgAV is often a benign and self-limited pathology in children and a more severe condition in adults, we 
analysed potential differences in genotype and allele frequencies of BAFF, APRIL and BAFFR between patients 
with IgAV stratified according to the age at disease onset. However, no statistically significant differences in 
BAFF, APRIL and BAFFR frequencies were detected when children (age ≤ 20 years) were compared to adults 
(age > 20 years) (Table 3).
We also examined whether differences in the genotype and allele frequencies of BAFF, APRIL and BAFFR 
could exist between patients with IgAV stratified according to the presence/absence of GI or renal manifestations. 
Accordingly, no statistically significant differences in BAFF, APRIL and BAFFR frequencies were found between 
patients with IgAV with or without GI manifestations (Table 3). This was also the case when patients with IgAV 
who developed renal manifestations were compared to those who did not exhibit these complications (Table 3).
Haplotype analyses of APRIL and BAFFR. Moreover, we compared haplotype frequencies of both 
APRIL and BAFFR between patients with IgAV and healthy controls as well as between patients with IgAV 
stratified according to the specific clinical characteristics of the disease mentioned above.
The haplotype analysis of APRIL and BAFFR did not yield additional information since haplotypes frequencies 
of both genes were similar in patients with IgAV when compared to healthy controls (Table 4). In addition, no 
statistically significant differences in APRIL and BAFFR haplotype frequencies were disclosed when patients with 
IgAV were stratified according to the age at disease onset or to the presence/absence of GI or renal manifestations 
(Supplementary Table S1, Supplementary Table S2 and Supplementary Table S3 online).
Discussion
Inflammatory diseases are pathologies that share common pathogenic molecular  mechanisms24,25. With this 
respect, cumulative knowledge clearly suggest that BAFF, APRIL and BAFF-R are key molecules involved in 
the development of B-lymphocytes1–5, that also play a relevant role in the pathogenic processes underlying 
immune-mediated  disorders6–8.
Taking into account these considerations, we aimed to determine whether BAFF, APRIL and BAFFR represent 
novel genetic risk factors for the pathogenesis of IgAV, a predominantly B-lymphocyte inflammatory leukocy-
toclastic vasculitis. For that purpose, we analysed a BAFF genetic variant (rs374039502), which colocalizes with 
the BAFF GCTGT>A insertion/deletion variant previously described as a common locus for the susceptibility 
to several autoimmune  diseases9,12, in the largest series of Caucasian patients diagnosed with IgAV ever assessed 
for genetic studies. Interestingly, this functional BAFF variant is an insertion-deletion in which five nucleotides 
are replaced by one (GCTGT>A), being this A the risk allele that creates a shorter 3´ UTR transcript, lacking a 
microRNA binding site, leading to higher levels of soluble BAFF, which in turn up-regulates humoral  immunity9. 
Additionally, we also assessed two tag variants within APRIL and BAFFR, which cover most of the variability of 
both genes, in our cohort of patients with IgAV. Our results showed no influence of BAFF, APRIL and BAFFR 
on the susceptibility to IgAV. Since an association between different genetic variants and an increased risk of 
nephritis or GI disease was disclosed in  IgAV26–29, we also evaluated whether BAFF, APRIL and BAFFR may be 
related to the increased risk of nephritis or GI complications in our patients with IgAV. However, data derived 
from our study do not support a role of BAFF, APRIL and BAFFR polymorphisms (assessed independently or 
combined conforming haplotypes) in the phenotype expression of IgAV, indicating that these genes do not 
represent risk factors for the severity of the disease.
A previous genetic study evaluated the potential involvement of BAFF rs374039502 on the susceptibility 
to and clinical expression of giant cell arteritis (GCA), another primary systemic vasculitis that, unlike IgAV, 
involves large and middle-sized blood  vessels30. Additionally, the role of this polymorphism on the pathogenesis 
of systemic sclerosis (SSc) was analysed in that  study30. Nevertheless, and in keeping with our data, a lack of asso-
ciation of BAFF rs374039502 with the susceptibility and severity of GCA and SSc were reported by the  authors30.
Table 2.  Genotype and allele frequencies of BAFF, APRIL and BAFFR in patients with IgAV and healthy 
controls. IgAV: IgA vasculitis; SNP: single nucleotide polymorphism. No statistically significant differences 
in BAFF, APRIL and BAFFR genotype and allele frequencies were disclosed when patients with IgAV were 




Genotypes, % (n) Alleles, % (n)
1/2 1/1 1/2 2/2 1 2
rs374039502 BAFF T/A
IgAV patients 91.9 (353) 8.1 (31) 0 95.9 (737) 4.1 (31)
Healthy controls 91.5 (733) 8.1 (65) 0.4 (3) 95.6 (1531) 4.4 (71)
rs11552708 APRIL G/A
IgAV patients 78.1 (299) 20.6 (79) 1.3 (5) 88.4 (677) 11.6 (89)
Healthy controls 77.9 (625) 20.4 (164) 1.6 (13) 88.1 (1414) 11.9 (190)
rs6608 APRIL C/T
IgAV patients 71.9 (277) 26.0 (100) 2.1 (8) 84.9 (654) 15.1 (116)
Healthy controls 70.0 (561) 27.6 (221) 2.5 (20) 83.7 (1343) 16.3 (261)
rs7290134 BAFFR A/G
IgAV patients 58.0 (224) 36.3 (140) 5.7 (22) 76.2 (588) 23.8 (184)
Healthy controls 57.2 (459) 36.4 (292) 6.5 (52) 75.3 (1210) 24.6 (396)
rs77874543 BAFFR G/C
IgAV patients 82.7 (316) 16.0 (61) 1.3 (5) 90.7 (693) 9.3 (71)
Healthy controls 83.0 (666) 16.6 (133) 0.4 (3) 91.3 (1465) 8.7 (139)
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Table 3.  Genotype and allele frequencies of BAFF, APRIL and BAFFR in patients with IgAV stratified 
according to specific clinical characteristics of the disease. IgAV: IgA vasculitis; GI: gastrointestinal. No 
statistically significant differences in BAFF, APRIL and BAFFR genotype and allele frequencies were disclosed 
between patients with IgAV stratified according to the age at disease onset or the presence/absence of GI or 
renal manifestations (p ≥ 0.05 in all the cases).
Polymorphism
Children 














TT 92.2 (284) 90.8 (69) 92.2 (190) 91.6 (163) 90.1 (128) 93.0 (225)
TA 7.8 (24) 9.2 (7) 7.8 (16) 8.4 (15) 9.9 (14) 7.0 (17)
AA 0 0 0 0 0 0
T 96.1 (592) 95.4 (145) 96.1 (396) 95.8 (341) 95.1 (270) 96.5 (467)
A 3.9 (24) 4.6 (7) 3.9 (16) 4.2 (15) 4.9 (14) 3.5 (17)
APRIL rs11552708
GG 78.1 (239) 77.9 (60) 76.7 (158) 79.7 (141) 81.1 (116) 76.3 (183)
GA 20.3 (62) 22.1 (17) 22.3 (46) 18.6 (33) 18.9 (27) 21.7 (52)
AA 1.6 (5) 0 1.0 (2) 1.7 (3) 0 2.1 (5)
G 88.2 (540) 89.0 (137) 87.9 (362) 89.0 (315) 90.6 (259) 87.1 (418)
A 11.8 (72) 11.0 (17) 12.1 (50) 11.0 (39) 9.4 (27) 12.9 (62)
APRIL rs6608
CC 70.8 (218) 76.6 (59) 69.6 (144) 74.7 (133) 75.5 (108) 69.8 (169)
CT 26.6 (82) 23.4 (18) 28.0 (58) 23.6 (42) 23.1 (33) 27.7 (67)
TT 2.6 (8) 0 2.4 (5) 1.7 (3) 1.4 (2) 2.5 (6)
C 84.1 (518) 88.3 (136) 83.6 (346) 86.5 (308) 87.1 (249) 83.7 (405)
T 15.9 (98) 11.7 (18) 16.4 (68) 13.5 (48) 12.9 (37) 16.3 (79)
BAFFR rs7290134
AA 58.9 (182) 54.5 (42) 55.0 (113) 62.0 (111) 60.1 (86) 56.8 (138)
AG 35.9 (111) 37.7 (29) 40.7 (85) 30.7 (55) 32.2 (46) 38.7 (94)
GG 5.2 (16) 7.8 (6) 4.3 (9) 7.3 (13) 7.7 (11) 4.5 (11)
A 76.9 (475) 73.4 (113) 75.1 (311) 77.4 (277) 76.2 (218) 76.1 (370)
G 23.1 (143) 26.6 (41) 24.9 (103) 22.6 (81) 23.8 (68) 23.9 (116)
BAFFR rs77874543
GG 83.0 (254) 81.6 (62) 81.6 (168) 84.1 (148) 83.1 (118) 82.5 (198)
GC 16.0 (49) 15.8 (12) 17.5 (36) 14.2 (25) 16.9 (24) 15.4 (37)
CC 1.0 (3) 2.6 (2) 1.0 (2) 1.7 (3) 0 2.1 (5)
G 91.0 (557) 89.5 (136) 90.3 (372) 91.2 (321) 91.5 (260) 90.2 (433)
C 9.0 (55) 10.5 (16) 9.7 (40) 8.8 (31) 8.5 (24) 9.8 (47)
Table 4.  Haplotype analysis of APRIL and BAFFR between patients with IgAV and healthy controls. IgAV: IgA 
vasculitis; OR: odds ratio; CI: confidence Interval.
APRIL haplotypes
p OR [95% CI]rs11552708 rs6608
G C – Ref.
A T 0.90 0.98 [0.73–1.31]
G T 0.20 0.77 [0.50–1.17]
A C 0.46 0.72 [0.26–1.79]
BAFFR haplotypes
p OR [95% CI]rs7290134 rs77874543
A G – Ref.
G G 0.57 0.93 [0.73–1.19]
G C 0.96 1.01 [0.72–1.39]
A C 0.16 2.08 [0.62–6.98]
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In summary, based on a large series of Caucasian patients, our results suggest that BAFF, APRIL and BAFFR 
genes do not contribute to the genetic network underlying IgAV.
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